SAN FRANCISCO, Dec. 9, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM:IMMU - News), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that combining milatuzumab with rituximab prolonged survival of animals injected with human mantle cell lymphoma cells. Results from this preclinical study were reported in an oral presentation at the 50th annual meeting of ASH by Dr. Lapo Alinari of the Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
